CLXS196X2101
51 evidence topics · 3 sources
Objective
Primary, secondary, and exploratory objectives of single-agent LXS196
“In this phase I trial, we aimed to evaluate the safety, preliminary efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of LXS196, and to determine the MTD and/or recommended dose for expansion (RDE) of LXS196 as a single agent in patients with MUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary objectives were to characterise the safety and tolerability and identify the MTD and/or RDE of LXS196 as a single agent in patients with MUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary objectives included investigation of the preliminary antitumour activity of LXS196 and evaluation of the PK and PD of LXS196.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory objectives included assessment of mutations in cancer driver genes by transcriptome and targeted DNA sequencing of baseline tumour biopsies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry title and purpose, including a combination part with HDM201
Location and study date
Novartis-sponsored multicenter study initiated on 1 February 2016
Registry protocol number and study dates
| Study characteristic | Quoted record |
|---|---|
| Other study ID number | “CLXS196X2101” |
| Study start (actual) | “2016-02-01” |
| Primary completion (actual) | “2022-01-07” |
| Study completion (actual) | “2022-01-07” |
Registry study sites in six countries
Study design
Dose escalation guided by a Bayesian logistic regression model, followed by expansion at the recommended dose
“Dose escalation was guided by safety, PK data and a two-parameter Bayesian Logistic Regression Model (BLRM) [21] employing escalation with overdose control (EWOC) criteria [22].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upon determination of the MTD/RDE, the expansion part of the study was opened to further evaluate the safety, tolerability, PK and PD of LXS196 at the RDE in patients with MUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Once-daily schedule followed by a twice-daily schedule
“Patients were initially treated on a QD schedule (100–1000 mg QD); however, due to toxicities reported at doses ≥500 mg QD, a BID schedule was then tested (200–400 mg BID).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following determination of the MTD in the QD dosing schedule, a BID schedule was introduced to explore whether alternative dosing may lead to better tolerability of LXS196.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry design and status: nonrandomized, open-label, single group; combination part terminated
| Study characteristic | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
Eligibility criteria
Adults with biopsy-proven progressive and measurable metastatic disease
“All patients were aged ≥18 years old and had biopsy-proven MUM with progressive and measurable disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 and requested to provide a tumour biopsy at baseline (pre-treatment) and on treatment at day 15 of cycle 1 (C1D15).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-naive or pretreated disease, with no limit on prior lines
“Patients were either treatment naïve or their disease had progressed (radiologically or clinically) on their most recent therapy. There was no eligibility limit to the number of prior lines of therapy, including PKC inhibitors other than LXS196.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion of cardiac disease, interacting medications, and impaired gastrointestinal function
“Exclusion criteria included impaired cardiac function or clinically significant cardiac diseases, receipt of concomitant medications known to be strong inducers or inhibitors of cytochrome P450 3A4/5 or known for QT prolongation risk, and impaired GI function that could interfere with absorption of LXS196.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry: measurable disease definition, central nervous system metastases, and laboratory exclusions
Treatment
Oral LXS196 once or twice daily in 28-day cycles
“During dose escalation, patients received oral LXS196 either once daily (QD; 100–1000 mg) or twice daily (BID; 200–400 mg) in 28-day cycles until disease progression, intolerable toxicity or withdrawal of consent (Supplementary Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dosing was omitted on the second day of the first cycle (C1D2) to allow for longer post-dose sampling in order to better characterise PK.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LXS196 was given on an empty stomach, at least 1 h before or 2 h after a meal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients enroled in the expansion part (n = 12) received LXS196 at the RDE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose adjustments and management of hypotension per protocol
“For patients who did not tolerate their assigned dosing schedule due to a treatment-related AE, dose adjustments were permitted to allow the patient to continue study treatment once the AE had resolved to ≤grade 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using dose-limiting toxicity as the primary endpoint
Dose-limiting toxicity period and evaluability for the dose-escalation model
“The DLT period lasted 28 days after the first dose of LXS196.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A patient was evaluable for the BLRM if the patient took at least 75% of the planned doses during the DLT period or had a DLT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nonclinical findings that anticipated hypotension and gastrointestinal toxicity
“Data from non-clinical single-dose and 4-week repeated dose toxicology studies in dog, suggested that a decrease in systolic blood pressure may be a potential toxicity observed in patients treated with LXS196. The 4-week toxicology study also identified the GI tract as a potential target of LXS196.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety assessments and adverse event grading
“Routine safety assessments, including laboratory assessments, physical examinations, vital signs and electrocardiograms (ECGs), were conducted at regular intervals throughout the study and more frequently as needed following patient assessment by the treating physician.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events (AEs) were assessed continuously according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tumor response by local RECIST v1.1 assessment
“Tumour response was assessed locally by computed tomography (CT) and/or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis, according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 at baseline, on C3D1 and every two cycles thereafter until cycle 11. After 11 cycles of treatment, response was evaluated every three cycles until the end of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry primary outcomes
Registry secondary outcomes of efficacy and pharmacodynamics
Statistical analysis description
Number of participants (Planned and analyzed)
Single-agent part: 68 participants treated, 56 in dose escalation and 12 in expansion
“A total of 68 patients with MUM were treated with LXS196 in this first-in-human study: 56 in the dose escalation part and 12 in dose expansion (Supplementary Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients enroled in dose escalation received doses ranging from 100–1000 mg QD (n = 38) and 200–400 mg BID (n = 18) until the RDE was established.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients received LXS196 doses ranging from 100–1000 mg once daily (QD; n = 38) and 200–400 mg twice daily (BID; n = 30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sample size selected for the dose-escalation model, without a formal calculation
“No hypothesis testing was planned in this study, and therefore, no formal sample size calculation was needed. The sample size was selected to ensure the BLRM had adequate operating characteristics when selecting the MTD/RDE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry: planned enrollment of the single-agent and HDM201 combination parts and actual enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (actual), single-agent and HDM201 combination parts | “107” |
Description of analysis sets
Population evaluable for maximum tolerated dose determination
Response population including participants without post-baseline assessment
“Two patients did not have post-baseline tumour assessments due to clinical disease progression before the first scheduled assessment. Hence, the BOR is unknown per RECIST 1.1, however, they are included in the denominator for ORR and DCR calculations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Estimate [95% CI] for ORR and DCR were obtained using Clopper and Pearson’s method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descriptive statistics and Kaplan-Meier estimation
“Data are presented using descriptive statistics and visualisations. Continuous variables are described with the mean and range. Categorical variables are described using counts and percentages. PFS is described using the Kaplan–Meier (KM) method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamic analysis restricted to the once-daily schedule
Results
Participant disposition
Final data cutoff of 7 January 2022: discontinuation in the once-daily schedule
Final data cutoff of 7 January 2022: duration of exposure
“As of the final data cut-off date (7 January 2022), a total of 68 patients had been treated with LXS196 and the median duration of exposure was 3.71 months (range: 1.81–15.28) and 4.6 months (range: 0.33–58.32) for patients in the QD and BID regimens, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single discontinuation due to an adverse event
“The only AE leading to discontinuation of LXS196 was an SAE of grade 3/4 hepatic failure in a patient treated in the BID schedule with known liver metastases and CTCAE grade 2 transaminases at study entry. The event was suspected to be related to underlying disease progression but was not confirmed by radiological assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Baseline characteristics by schedule and at the recommended dose for expansion
Demographics, metastatic sites, and prior therapy
“The median age was 56.0 years, 36 (52.9%) were male, and most (n = 62; 91.2%) had a performance status of 0. The majority of patients (n = 60; 88.2%) had liver metastases, 27 of whom (14 in the BID schedule and 13 in the QD schedule) had only liver metastases and no other sites of disease at study entry.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other reported metastatic sites with an incidence of at least 10% included lung (n = 18, 26.5%), bone (n = 13, 19.1%), lymph node (n = 8, 11.8%) and skin (n = 7, 10.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 59 patients (86.8%) had received prior systemic therapy; the majority having received either one (n = 37, 54.4%) or two prior regimens (n = 14, 20.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of patients (n = 31, 45.6%) had PD as the best overall response (BOR) to their last prior therapy and in these patients, the median time from initiation to discontinuation of last prior therapy was 63 days (range: 14–515).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No patients had received prior tebentafusp.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
GNAQ, GNA11, and BAP1 mutations in baseline tumor biopsies
“Mutations in the GNAQ and GNA11 genes are tabulated (Supplementary Table 5A); of the 48 patients assessed, 28 were mutant in GNA11 (of which 22 had allele Q209L and 6 had R183C), 16 were mutant in GNAQ (of which 13 had allele Q209P, two Q209L, and one R183Q), and 4 were not called mutant in either gene as the allele fraction was below the limit of detection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BAP1 mutations resulting in a protein coding change were detected in 44% (21/48) of patients (Supplementary Table 5B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Best overall response and progression-free survival by schedule and at the recommended dose for expansion
All participants: response, duration of response, and duration of stable disease
“Clinical activity was observed in 6/66 (9.1%) evaluable patients achieving response (CR/PR), with a median duration of response of 10.15 months (range: 2.99–41.95); 45/66 had stable disease (SD) per RECIST v1.1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median duration of response for all patients with a RECIST response (n = 6) was 10 months (2.99–41.95) and median duration of SD (n = 45) was 5.32 months (2.07–30.23).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Twice-daily schedule and the recommended dose for expansion of 300 mg twice daily: response
“The ORR in the BID schedule was 13.3% (95% CI: 3.8–30.7) and the disease control rate (DCR) was 73.3% (95% CI: 54.1–87.7) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 18 evaluable patients treated at the RDE of 300 mg BID, 2 (11.1%) had a BOR of PR and 12 (66.7%) had SD (including 3 patients with >30% tumour reduction/unconfirmed PR).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR at the RDE was 11.1% (95% CI: 1.4–34.7) and the DCR was 77.8% (95% CI: 52.4–93.6) (Fig. 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression-free survival in all participants, the twice-daily schedule, and at the recommended dose for expansion
“No patients were censored and 100% of PFS events were reported as of the data cut-off date. Of the 68 events, 66 had disease progression and 2 patients had died. The estimated median PFS was 3.6 months (95% CI: 3.5–5.4) and the estimated PFS rate at 6 months by the KM method was 29.4% (95% CI: 19.1–40.4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the BID schedule, the estimated median PFS was 4.1 months (95% CI: 3.5–7.2) and the estimated PFS rate at 6 months by the KM method was 33.3% (95% CI: 17.5–50).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the RDE of 300 mg BID, the estimated median PFS was 3.7 months (95% CI: 2.1–5.4) and the estimated PFS rate at 6 months by the KM method was 27.8% (95% CI: 10.1–48.9) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparison by the authors with the first-generation PKC inhibitor AEB071
“Regarding efficacy, across all doses tested the ORR was 8.8% with LXS196 versus 3% with AEB071, and 67% of patients had SD as their best response with LXS196 versus 50% with AEB071 (median duration of SD: 5.32 versus 3.75 months, respectively). The estimated median PFS was similar at 3.6 months (95% CI: 3.5–5.4) with LXS196 versus 3.5 months (95% CI: 2.5–3.6) with AEB071.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complete response at month 31 reported by the sponsor
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Dose-limiting toxicities and declaration of the maximum tolerated doses and recommended dose for expansion
“First cycle dose-limiting toxicities (DLTs) were observed in 7/38 (18.4%) QD and 2/17 (11.8%) BID patients. Hypotension was the most common DLT, occurring at doses ≥500 mg/day, and manageable with LXS196 interruption and dose reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MTDs were declared at 500 mg QD and 400 mg BID, based on the BLRM and EWOC principles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following the BLRM recommendation guided by EWOC and review of all available safety and PK data, the RDE was declared at 300 mg BID (Supplementary Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 55 patients evaluable for MTD/RDE determination, DLTs were observed in nine (16.4%) patients (seven patients treated in the QD schedule and two patients in the BID schedule) (Table 2A). The most common DLT was hypotension (n = 6; 10.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other DLTs included nausea and vomiting, neutropenia and generalised oedema (one patient each; 1.8%). GI-related DLTs resolved with temporary interruption of study drug and treatment with anti-emetics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hypotension as a dose-limiting toxicity: timing, presentation, and resolution
“In the QD schedule, hypotension leading to drug interruption and subsequent dose reduction occurred in five patients treated at doses ≥500 mg (two grade 3 events at 500 mg QD, one grade 4 event at 800 mg QD, one grade 4 and one grade 2 event at 1000 mg QD). These events most commonly occurred within 1 to 4 h after the first or second dose and were sometimes accompanied by a transient loss of consciousness with preceding dizziness and sweating.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most events resolved within minutes, some within 4 h, with an infusion of intravenous fluids and 2 patients experienced recurrence of hypotension with 1 patient requiring further LXS196 dose reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One DLT of grade 3 hypotension was reported in a patient treated at the highest BID dose tested (400 mg BID).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events suspected to be related to LXS196 by schedule and at the recommended dose for expansion
Grade 3 or higher serious adverse events regardless of relationship, by schedule
| Preferred term | All QD, n = 38 | 300 mg BID (RDE), n = 18 | All BID, n = 30 | All patients, N = 68 |
|---|---|---|---|---|
| Participants with at least 1 serious adverse event, n (%) | “7 (18.4)”View highlighted excerpt for this quote | “5 (27.8)”View highlighted excerpt for this quote | “7 (23.3)”View highlighted excerpt for this quote | “14 (20.6)”View highlighted excerpt for this quote |
| Hypotension, n (%) | “5 (13.2)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “1 (3.3)”View highlighted excerpt for this quote | “6 (8.8)”View highlighted excerpt for this quote |
| Pneumonia, n (%) | “2 (5.3)”View highlighted excerpt for this quote | “1 (5.6)”View highlighted excerpt for this quote | “1 (3.3)”View highlighted excerpt for this quote | “3 (4.4)”View highlighted excerpt for this quote |
Adverse events regardless of relationship, serious adverse events, and tolerability of the two schedules
“The majority of patients (n = 66; 97.1%) experienced an AE regardless of study drug relationship during the study; 29 (42.6%) of these patients experienced AEs of grade 3/4 (Supplementary Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent AEs with LXS196 (all grades, all doses, both schedules) were nausea (n = 48; 70.6%), diarrhoea (n = 37; 54.4%), vomiting (n = 26; 38.2%), fatigue (n = 19; 27.9%), increased alanine aminotransferase (ALT, n = 18; 26.5%), constipation (n = 17; 25%), asthenia (n = 15; 22.1%) and hypotension (n = 15; 22.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent AEs of grade ≥3, regardless of study drug relationship, were hypotension (n = 6; 8.8%), increased aspartate aminotransferase (AST, n = 5; 7.4%) and increased ALT (n = 4; 5.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Serious AEs (SAEs) were observed in 14 (20.6%) patients, and all were grade 3/4; the most frequent were hypotension (n = 6; 8.8%) and pneumonia (n = 3; 4.4%) (Table 2C). BID appeared to be better tolerated than QD dosing, with fewer treatment-related grade 3/4 AEs and treatment-related SAEs. Grade 3/4 hypotension was more common in the QD versus the BID groups (13.2% versus 3.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interruptions and dose reductions as described by the authors
Study limitations
Summary
CLXS196X2101 is a nonrandomized, open-label, single-group phase 1 study of LXS196 (darovasertib) as a single agent, without crizotinib. No hypothesis testing was planned and no formal sample size calculation was made; data are presented descriptively. Of the 68 participants, 59 (86.8%) had received prior systemic therapy, and none had received prior tebentafusp. Participants were treated across once-daily doses of 100 to 1000 mg (n = 38) and twice-daily doses of 200 to 400 mg (n = 30), and 18 were evaluable at the recommended dose for expansion of 300 mg twice daily. Tumour response was assessed locally per RECIST v1.1. The ORR denominator differs between the text (6 of 66 evaluable participants, 9.1%) and the results table, which includes 2 participants without post-baseline assessment in a denominator of 68; the 95% CI of the 6-month PFS rate in all participants is 19.1 to 40.4 in the text and 19.1 to 29.2 in the table. Pharmacodynamic analysis was not performed on tumour samples from the twice-daily schedule, the authors note that the C1D15 biopsy timepoint might be too late to observe transient changes, and the sequencing panel did not include CYSLTR2 and PLCB4. The combination part with HDM201 was terminated early for business reasons. No quality-of-life or patient-reported outcome results were reported; the registry outcomes cover dose-limiting toxicities, adverse events, dose modifications, ORR, PFS, and pharmacodynamics.
Exploratory phase 1 design without formal statistical testing
Timing of on-treatment biopsies for pharmacodynamic assessment
“There are several possible explanations for the lack of correlation between reductions in pMARKCS/pPKCd and clinical activity. One possibility is that the PKC signalling pathway is highly sensitive to LXS196 exposure, and a C1D15 timepoint might be too late to observe transient changes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote